In this secondary analysis of a randomized clinical trial of 180 neonates with hypoxic ischemic encephalopathy and complete biomarker and outcome data, erythropoietin treatment did not affect the measured circulating biomarker concentrations. The gene discussed is EPO; the disease is perinatal asphyxia.